Anti-CD19 CAR-T Structures With Heavy-Chain CDR Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for B-cell malignancies and autoimmune disorders targeting CD19 expression are limited by the efficiency and specificity of conventional antibodies and CAR-T structures, which can be improved by utilizing heavy chain-only antibodies and engineered CAR-T cells with optimized CDR sequences for enhanced antigen binding and therapeutic efficacy.
Innovation Solution
Development of antibodies and CAR-T structures comprising heavy chain variable regions with specific CDR sequences, including CDR1, CDR2, and CDR3, which are engineered to bind CD19 with high affinity and specificity, and are produced in UniRat animals or recombinantly, for use in treating B-cell disorders and autoimmune diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies and CAR-T structures are used to target CD19, then therapeutic treatment can be provided, but the efficiency and specificity are limited
Solution Approach 1:
The patent extracts and utilizes only the heavy chain variable region (VH) with specific CDR sequences from conventional antibodies, creating simplified heavy chain-only antibodies and CAR-T structures that maintain CD19 binding specificity while eliminating the complexity of light chains and constant regions. This extraction approach directly improves binding efficiency without the structural complexity of conventional antibodies.
Solution Approach 2:
The patent changes the structural parameters of antibodies by using heavy chain-only configurations with specifically engineered CDR sequences (particularly CDR3 length and composition). These parameter changes in the variable region structure enable enhanced binding affinity and specificity to CD19 while simplifying the overall molecular architecture compared to conventional IgG structures.
2Productivity
If heavy chain-only antibodies with engineered CDR sequences are used, then binding affinity and therapeutic efficacy are enhanced, but production complexity increases
Solution Approach 1:
The patent performs preliminary engineering of the CDR sequences during the design phase, particularly optimizing CDR3 length and amino acid composition before production. This preliminary action ensures that the heavy chain-only antibodies and CAR-T structures are pre-optimized for high binding affinity and therapeutic efficacy, reducing the need for complex post-production modifications and simplifying the overall manufacturing process.
Solution Approach 2:
The patent creates universal heavy chain variable region templates with optimized CDR sequences that can be applied across different antibody formats and CAR-T structures. This universality allows the same engineered VH framework to be used in multiple therapeutic applications against CD19, reducing production complexity through standardized manufacturing approaches while maintaining enhanced therapeutic efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered antibodies and CAR-T cells demonstrate improved binding, activation, and therapeutic efficacy, including enhanced in vitro and in vivo T-cell expansion, reduced exhaustion, and tumor control, offering potential treatments for disorders like diffuse large B-cell lymphoma, acute lymphoblastic leukemia, non-Hodgkin's lymphoma, systemic lupus erythematosus, and rheumatoid arthritis.
Implementation Method 1
antibodies and CAR-T structures that bind to CD19... heavy chain variable regions with specific CDR sequences, including CDR1, CDR2, and CDR3, which are engineered to bind CD19 with high affinity and specificity
Implementation Method 2
the association of the heavy chain and light chain is due in part to a hydrophobic interaction between the light chain constant region and the CH1 constant domain of the heavy chain
Data Source
AI summary
Anti-CD19 antibodies (e.g., UniAbs™) and CAR-T structures are disclosed, along with methods of making such antibodies and CAR-T structures, compositions, including pharmaceutical compositions, comprising such antibodies and CAR-T structures, and their use to treat disorders that are characterized by the expression of CD19.